Newer agents, including anti-PD-1 (programmed cell death protein 1) antibodies and anti-PD-L1 (programmed cell death protein ligand-1) antibodies, have also shown marked activity against melanoma and other advanced cancers [7-10], further expanding the role of cancer immunotherapy. Here, PDCD1 is linked to cancer.